Efficacy studies for cancer, bacterial and virus infections: vaccines, drug compounds, and antibodies
Ready to de-risk your efficacy strategy?
Discuss your study design, model selection, and CRO pathway with our experts.
Efficacy Studies for Cancer, Bacterial, and Viral Infections: Validating Therapeutic Effectiveness Before Clinical Application
Demostrating efficacy in relevant preclinical models is a critical step in drug development.
Well-designed efficacy studies provide early evidence that a candidate can meaningfully treat or prevent disease and help de-risk downstream clinical investment.
Animal and advanced preclinical models enable the assessment of therapeutic impact under controlled conditions, supporting informed decisions on candidate selection, dose rationale, and development strategy.
Why
Efficacy Studies Matter
Robust efficacy data:
• confirms biological relevance and therapeutic potential
• Strengthens investor and partner confidence
• Support regulatory interactions and progression to clinical trials
• Prevents costly late-stage failure by identifying limitations early
Our Role as an Intermediary
We do not operate as a single execution CRO.
Instead, we act as a strategic intermediary, ensuring that your efficacy studies are performed by the most suitable CRO and model for your specific therapy.
We combine scientific insight with a curated CRO network to ensure fit-for-purpose study execution, rather than one-size-fits-all solutions.
How We Work:
1. Understand your therapy: Indication, mechanism of action, modality, and development stage
2. Define the optimal efficacy strategy: Translational relevance, endpoints, and success criteria
3. Identify and contract the best-fit CRO: Based on model expertise, track record, regulatory acceptance, and capacity
4. Oversee study execution: Scientific oversight, milestone monitoring, and risk mitigation
5. Translate results: Clear interpretation for internal teams, investigators, and regulators
What We Deliver:
CRO selection and matchmaking
• Expert shortlisting for efficacy studies (cancer, bacterial, viral)
• Fit-for-purpose partners – no one-size-fits-all
• Track record, model expertise & regulatory relevance
Tailored Model strategy
• Species selection & challenge models
• Translational relevance & endpoints
• Success criteria aligned to indication & MOA
Study Design Review
• Scientific & regulatory alignment
• Endpoint definition & power justification
• Dosing rationale & comparator strategy
Interpretation & Decision-Ready Outputs
• Consolidated results
• Clear insights for internal, investor, and regulatory use
Ready to validate your efficacy strategy?
Ensure your preclinical studies deliver credible, decision-ready evidence, before you commit to execution.
Confidential · Independent · No obligation
Contact Form
Interested in testing efficacy of vaccines, antibodies or drug compounds in cancer or infection models? Want to discuss how our animal models, validated designs, or CRO partnerships could support your project? Fill in the form below and our team will get back to you within 1-2 business days.